In South San Francisco and San Diego, on April 3, 2026, ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a company concentrating on oncology treatments targeting therapeutic resistance mechanisms, revealed that on April 1, 2026, they provided a new non-executive employee, who joined in March 2026, with 80,000 non-qualified stock options and 15,000 restricted stock units.